Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations

Abstract Human papilloma virus infection (HPV) is the most common sexually transmitted disease. Little is known about male infection. Nonavalent vaccine against types 6/11/16/18/31/33/45/52/58 was approved and neutral gender immunization programs have been proposed. This study evaluates the potentia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liana Bosco, Nicola Serra, Teresa Fasciana, Daniela Pistoia, Marco Vella, Leonardo Di Gregorio, Rosaria Schillaci, Antonino Perino, Gloria Calagna, Alberto Firenze, Giuseppina Capra
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e55593e95e4c4b55874483f88980e030
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e55593e95e4c4b55874483f88980e030
record_format	dspace
spelling	oai:doaj.org-article:e55593e95e4c4b55874483f88980e0302021-12-02T12:11:06ZPotential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations10.1038/s41598-021-83639-62045-2322https://doaj.org/article/e55593e95e4c4b55874483f88980e0302021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83639-6https://doaj.org/toc/2045-2322Abstract Human papilloma virus infection (HPV) is the most common sexually transmitted disease. Little is known about male infection. Nonavalent vaccine against types 6/11/16/18/31/33/45/52/58 was approved and neutral gender immunization programs have been proposed. This study evaluates the potential impact of nonavalent vaccine compared to quadrivalent in male living in Sicily (Italy). 58.7% of samples were HPV positive and forty-four types of HPV were identified. A significant higher estimated coverage of nonavalent vaccine than quadrivalent was observed (64.3% vs. 45.8%), with absolute and relative additional impact of 20.1% and 47.2%, respectively. Low impact of the vaccine were calculated as the empirical probability of HPV genotypes 6/11/16/18/31/33/45/52/58 alone or in combination; the high impact as empirical probability of HPV6/11/16/18/31/33/45/52/58 genotypes alone or in association with other genotypes. The potential impact of the nonavalent vaccine vs quadrivalent was significant for low and high impact (29.7% > 18:8%; 34:6% > 26.6%, respectively). Particularly, in men with lesions and risky sexual contact was significant only for low impact (35.5% > 29.7%; 31.4% > 19.7%, respectively). In partners with positive females was significant for low impact (26.3% > 15.1%) and high impact (33.7% > 23.2%). Nonavalent vaccine offers broader protection in men with HPV positive partners, who would have a potential role in the transmission of the infection.Liana BoscoNicola SerraTeresa FascianaDaniela PistoiaMarco VellaLeonardo Di GregorioRosaria SchillaciAntonino PerinoGloria CalagnaAlberto FirenzeGiuseppina CapraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Liana Bosco Nicola Serra Teresa Fasciana Daniela Pistoia Marco Vella Leonardo Di Gregorio Rosaria Schillaci Antonino Perino Gloria Calagna Alberto Firenze Giuseppina Capra Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations
description	Abstract Human papilloma virus infection (HPV) is the most common sexually transmitted disease. Little is known about male infection. Nonavalent vaccine against types 6/11/16/18/31/33/45/52/58 was approved and neutral gender immunization programs have been proposed. This study evaluates the potential impact of nonavalent vaccine compared to quadrivalent in male living in Sicily (Italy). 58.7% of samples were HPV positive and forty-four types of HPV were identified. A significant higher estimated coverage of nonavalent vaccine than quadrivalent was observed (64.3% vs. 45.8%), with absolute and relative additional impact of 20.1% and 47.2%, respectively. Low impact of the vaccine were calculated as the empirical probability of HPV genotypes 6/11/16/18/31/33/45/52/58 alone or in combination; the high impact as empirical probability of HPV6/11/16/18/31/33/45/52/58 genotypes alone or in association with other genotypes. The potential impact of the nonavalent vaccine vs quadrivalent was significant for low and high impact (29.7% > 18:8%; 34:6% > 26.6%, respectively). Particularly, in men with lesions and risky sexual contact was significant only for low impact (35.5% > 29.7%; 31.4% > 19.7%, respectively). In partners with positive females was significant for low impact (26.3% > 15.1%) and high impact (33.7% > 23.2%). Nonavalent vaccine offers broader protection in men with HPV positive partners, who would have a potential role in the transmission of the infection.
format	article
author	Liana Bosco Nicola Serra Teresa Fasciana Daniela Pistoia Marco Vella Leonardo Di Gregorio Rosaria Schillaci Antonino Perino Gloria Calagna Alberto Firenze Giuseppina Capra
author_facet	Liana Bosco Nicola Serra Teresa Fasciana Daniela Pistoia Marco Vella Leonardo Di Gregorio Rosaria Schillaci Antonino Perino Gloria Calagna Alberto Firenze Giuseppina Capra
author_sort	Liana Bosco
title	Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations
title_short	Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations
title_full	Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations
title_fullStr	Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations
title_full_unstemmed	Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations
title_sort	potential impact of a nonavalent anti hpv vaccine in italian men with and without clinical manifestations
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e55593e95e4c4b55874483f88980e030
work_keys_str_mv	AT lianabosco potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations AT nicolaserra potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations AT teresafasciana potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations AT danielapistoia potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations AT marcovella potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations AT leonardodigregorio potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations AT rosariaschillaci potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations AT antoninoperino potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations AT gloriacalagna potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations AT albertofirenze potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations AT giuseppinacapra potentialimpactofanonavalentantihpvvaccineinitalianmenwithandwithoutclinicalmanifestations
_version_	1718394663552942080

Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations

Ejemplares similares